| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:KT182
CAS:1402612-62-7
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
MedBioPharmaceutical Technology Inc
|
| Tel: |
021-69568360 18916172912 |
| Email: |
order@med-bio.cn |
| Products Intro: |
Product Name:4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone
CAS:1402612-62-7
Purity:98% Package:10mg; 5mg Remarks:Medbio
|
|
| | [4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone Basic information |
| Product Name: | [4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone | | Synonyms: | [4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone;KT182;Methanone, [4-[3'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-;KT182 >=98% (HPLC);[4-[4-[3-(hydroxymethyl)phenyl]phenyl]triazol-1-yl]-(2-phenyl-1-piperidyl)methanone;KT182,KT-182 | | CAS: | 1402612-62-7 | | MF: | C27H26N4O2 | | MW: | 438.52 | | EINECS: | | | Product Categories: | | | Mol File: | 1402612-62-7.mol | ![[4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone Structure](CAS/20200515/GIF/1402612-62-7.gif) |
| | [4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone Chemical Properties |
| Boiling point | 684.3±65.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble10mg/mL, clear | | pka | 14.21±0.10(Predicted) | | form | powder | | color | white to beige |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 |
| | [4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone Usage And Synthesis |
| Description | KT182 is a potent inhibitor of α/β-hydrolase domain-containing protein 6 (ABHD6) with IC50 values of 1.7, 15.1, and 0.24 nM using Neuro2a membrane proteomes, recombinant ABHD6 in HEK293T cells, and Neuro2a cells in situ, respectively. Following administration of KT182 (1 mg/kg, i.p.) in mice, ABHD6 is inactivated in liver and brain extracts, suggesting that it is brain-penetrant, unlike the closely related compound KT203 . | | in vitro | the in-vitro potencies were tested for kt182 and the results found that kt182 could potently inhibit abhd6 as measured by gelbased competitive abpp and 2-ag hydrolysis assays. moreover, the in-situ potencies were measured by treating neuro2a cells with varying concentrations of kt182 for 4 h, and it was found that kt182 could inhibit abhd6 with ic50 values in the subnanomolar range [1]. | | in vivo | in animal study, mice were treated intraperitoneally with kt182 at various doses (0.1-1 mg/kg) for 4 h, and the results found that kt182 could produce near-complete blockade of abhd6 in the liver at the highest dose tested. moreover, kt182 at lower doses maintained around 80% inhibition of abhd6 in the liver and kt182 at higher doses showed impressive selectivity in the mouse liver, exhibiting little cross-reactivity against the numerous carboxylesterase enzymes. in addition, kt182 could also completely inactivate abhd6 in the mouse brain at 1 mg/kg [1]. | | IC 50 | < 5 nm | | storage | Store at -20°C | | references | [1] hsu kl, tsuboi k, chang jw, whitby lr, speers ae, pugh h, cravatt bf. discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β-hydrolase domain containing 6 (abhd6). j med chem. 2013 nov 14;56(21):8270-9. |
| | [4-[3′-(Hydroxymethyl)[1,1′-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone Preparation Products And Raw materials |
|